Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
A fire broke out at a Novo Nordisk office building in Bagsværd, Denmark on Tuesday. No employees were hurt but one of the firefighters was taken to hospital for observation, a company spokesperson told Endpoints News.
“There are no indications of any connection between this fire and the previous fires, nor of any criminal activity relating to any of them,” the spokesperson added. This is the third fire that has hit Novo Nordisk in Denmark in recent weeks. On May 22, an office building caught alight and another fire occurred on May 16 at a construction site.
Thermo Fisher Scientific’s clinical research business has invested $58 million into a new clinical research lab in Middleton, WI, with a focus on small molecules and biologics. The new build will allow for around 350 new jobs for scientists and lab support staffers, the company said Tuesday.
Pharma company Lupin has appointed Abdelaziz Toumi as the new CEO of its API manufacturing arm, dubbed Lupin Manufacturing Solutions, the company said Monday.
Therapeutic protein manufacturer LFB Biomanufacturing is expanding its site in Alès, France, with a €20 million ($21.5 million) budget. The expanded site will add 50 new jobs by 2026, the company said on June 14.
EuroAPI and oncology biotech Priothera have entered a five-year agreement in which EuroAPI will manufacture Priothera’s mocravimod in Budapest, the companies said Tuesday. Mocravimod is in a Phase 3 acute myeloid leukemia study.
CDMO Kemwell Biopharma and RevOpsis Therapeutics have entered a manufacturing partnership in which Kemwell will manufacture RevOpsis’ preclinical biologic candidate for neovascular age-related macular degeneration, according to a Monday release.
Swiss CDMO Celonic opened a new biologics center and plant in Basel, the company said Tuesday. The site has biologics production and will coordinate with Celonic’s GMP manufacturing site in Heidelberg, Germany.
Primrose Bio has secured equity investment from 1315 Capital to further develop three of its manufacturing assets including Prima RNApols, which are RNA polymerase enzymes for mRNA manufacturing. There is also the microbial expression system, dubbed Pfenex Expression Technology, and its conjugate vaccine carrier protein, named CRM197.
Charles River Laboratories and the biotech Captain T Cell are partnering on retrovirus vector production. Captain T Cell would gain access to Charles River’s CDMO offerings, according to a Monday release. Captain T cell is working on a Phase 1 TCR-T cell therapy for solid tumors.
Beam Therapeutics revealed preclinical and GMP data touting its automated manufacturing process for CD34+ hematopoietic stem and progenitor cell genetic therapies. The process is used to make the biotech’s Phase 1/2 sickle cell disease asset, dubbed BEAM-101. The data were revealed at the European Hematology Association congress.
London-based investment firm Great Point Partners is acquiring the German CDMO Lyocontract, which specializes in producing liquid and freeze-dried parenteral drugs in vials, the companies said June 13. Lyocontract has one facility in Ilsenburg, Germany, that provides services in aseptic liquid filling, lyophilization and packaging.
Manufacturers CordenPharma and Wacker said that they are pandemic ready in that they can produce 80 million vaccines per year and are on “stand by mode” for the next five years, the companies said Wednesday.